Hims & Hers Begins Selling Zepbound

A Reuters report1 noted that Hims & Hers began selling various Eli Lilly drugs on their platform—both branded forms of tirzepatide—including Zepbound, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but for the treatment of type 2 diabetes. The telehealth company is also now selling generics of Novo's diabetes drug, liraglutide, approved for type 2 diabetes and obesity indications.

GLP-1s have traditionally treated type 2 diabetes, but surged in popularity for battling weight loss; they have also recently been approved in other indications, such as cardiovascular disease prevention and sleep apnea.2

On the Hims & Hers website, both the Zepbound and Mounjaro injections will run customers $1,899 a month. Meanwhile, Lilly’s LillyDirect platform3,4 that was launched back in January 2024—which is known for providing resources for disease management, featuring access to independent healthcare providers, support, and direct home delivery of certain Lilly medicines through third-party pharmacy dispensing services—offers different prices.

In fact, the pharma company released a statement5 yesterday, noting that “Eli Lilly and Company (NYSE: LLY) has no affiliation with hims & hers. Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25. For those who self-pay, Zepbound is available starting at $349 per month on LillyDirect.”

Hims & Hers also sells Novo Nordisk’s Wegovy (semaglutide), another GLP-1 for weight management.

References

1. SK Sneha, Singh P. Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform. Reuters. April 2, 2025. Accessed April 2, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/hims-hers-sell-lillys-zepbound-its-telehealth-platform-2025-04-01/

2. Saraceno N. Beyond the GLP-1 Headlines. Pharmaceutical Commerce. February 12, 2025. Accessed April 2, 2025. https://www.pharmaceuticalcommerce.com/view/beyond-the-glp-1-headlines

3. Tracy D. Lilly Introduces Single-Dose Vials of Zepbound, Expanding Access for Adults with Obesity. Pharmaceutical Commerce. August 27, 2024. Accessed April 2, 2025. https://www.pharmaceuticalcommerce.com/view/lilly-introduces-single-dose-vials-zepbound-expanding-access-adults-obesity

4. Saraceno N. Lilly Adds New Zepbound Vial Doses to the Mix. Pharmaceutical Commerce. February 25, 2025. Accessed April 2, 2025. https://www.pharmaceuticalcommerce.com/view/lilly-adds-new-zepbound-vial-doses

5. Statement: Lilly has no affiliation with hims & hers. Lilly. April 1, 2025. Accessed April 2, 2025. https://investor.lilly.com/news-releases/news-release-details/statement-lilly-has-no-affiliation-hims-hers